Search results
Showing 16 to 30 of 100 results for methotrexate
Delgocitinib for treating moderate to severe chronic hand eczema ID6408
In development [GID-TA11506] Expected publication date: TBC
In development [GID-TA11566] Expected publication date: 21 May 2025
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221
In development [GID-TA11183] Expected publication date: 21 May 2025
In development [GID-TA11233] Expected publication date: 04 June 2025
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults.
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: TBC
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)
This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.
Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral...
Tocilizumab for the treatment of rheumatoid arthritis (TA247)
Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they have not worked well enough.
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive cutaneous T-cell lymphoma in adults.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.